The HDLs co-loaded with DOX and immunoadjuvants could specifically target tumor cells through recognition of surface scavenger receptor class B type I (SR-BI), followed by internalization of CpG-DOX into tumor cells, DOX-induced TAAs release, and CpG-triggered antigen presentation by DCs, as well as potent anti-tumor T cell response. The gene discussed is SCARB1; the disease is neoplasm.